Repertoire Genesis Inc. (Headquarters: Ibaraki, Osaka) entered into a non-exclusive Collaboration and Option to License Agreement with Cellectis SA. (Headquarters: Paris, France) on the development of a TCR-T cell product against NY-ESO-1 with the TAL Nuclease technology for cancer immunotherapy.

View original content:Press Release